Comparison of analgesia by intravenous butorphanol and meperidine in patients with post-operative pain
- PMID: 318908
- DOI: 10.1007/BF03006816
Comparison of analgesia by intravenous butorphanol and meperidine in patients with post-operative pain
Abstract
Intravenous doses of butorphanol tartrate (0.5 mg, 1.0 mg and 2.0 mg) and meperidine hydrochloride (20 mg and 40 mg) were compared under controlled conditions employing a double blind study design. Informed consent was obtained from all post-operative patients suffering from moderate to severe pain who participated in this study. Approximately 25 patients were included in each group. The data from 125 patients were subjected to statistical analysis. The results indicated that butorphanol is approximately 40 to 50 times more potent than meperidine. In addition, at most of the time intervals, there were no statistically significant differences between the responses to butorphanol 0.5 mg and 1 mg and meperidine 20 mg and 40 mg; but the response to butorphanol 2 mg was significantly (p less than 0.05) better than the low dose of each agent. The low doses of butorphanol (0.5 mg) and meperidine (20 mg) appear to have an effective duration of action of less than two hours. The larger doses (butorphanol 1.0 mg and 2.0 mg and meperidine 40 mg) appeared to produce a two- to four-hour duration of action. The largest butorphanol dose (2.0 mg) appeared to produce the longest duration of action. A comparison of the test groups with respect to the incidence and type of side effects showed that butorphanol 2.0 mg produced a greater incidence of drowsiness (39 per cent). The overall incidence of drowsiness for patients receiving either the 0.5 mg or 1.0 mg dose of butorphanol was 12 per cent, as compared with an 8 per cent overall incidence in the meperidine group. The incidence of other side effects was relatively low in all test groups. No significant differences were noted among the groups with regard to the onset (usually less than or equal to 30 minutes post-therapy) or the duration (usually less than or equal to 2 hours) of side effects. Butorphanol appears to be a safe and effective analgesic for the relief of moderate to severe post-operative pain.
Similar articles
-
Intramuscular butorphanol and meperidine in postoperative pain.Clin Pharmacol Ther. 1976 Sep;20(3):359-64. doi: 10.1002/cpt1976203359. Clin Pharmacol Ther. 1976. PMID: 782774 Clinical Trial.
-
Butorphanol and meperidine compared in patients with acute ureteral colic.J Urol. 1979 Oct;122(4):455-7. doi: 10.1016/s0022-5347(17)56460-5. J Urol. 1979. PMID: 384024 Clinical Trial.
-
Comparison of butorphanol tartrate and meperidine in moderate to severe renal colic.Urology. 1987 Mar;29(3):339-45. doi: 10.1016/0090-4295(87)90088-4. Urology. 1987. PMID: 3548009 Clinical Trial.
-
Drug therapy reviews: evaluation of butorphanol tartrate.Am J Hosp Pharm. 1979 Dec;36(12):1683-91. Am J Hosp Pharm. 1979. PMID: 393109 Review.
-
[Intranasal opioids for acute pain].Rev Esp Anestesiol Reanim. 2006 Dec;53(10):643-52. Rev Esp Anestesiol Reanim. 2006. PMID: 17302079 Review. Spanish.
Cited by
-
Opioid agonist-antagonist drugs in acute and chronic pain states.Drugs. 1991 Mar;41(3):326-44. doi: 10.2165/00003495-199141030-00002. Drugs. 1991. PMID: 1711441 Review.
-
The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.Eur J Clin Pharmacol. 1994;47(1):57-60. doi: 10.1007/BF00193479. Eur J Clin Pharmacol. 1994. PMID: 7988625 Clinical Trial.
-
Bier's block using lignocaine and butorphanol.J Anaesthesiol Clin Pharmacol. 2011 Oct;27(4):465-9. doi: 10.4103/0970-9185.86580. J Anaesthesiol Clin Pharmacol. 2011. PMID: 22096277 Free PMC article.
-
A double-blind study on the effects of butorphanol compared with morphine in balanced anaesthesia.Can Anaesth Soc J. 1978 Sep;25(5):392-7. doi: 10.1007/BF03006568. Can Anaesth Soc J. 1978. PMID: 359108 Clinical Trial.
-
The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.Eur J Clin Pharmacol. 1993;45(6):559-62. doi: 10.1007/BF00315315. Eur J Clin Pharmacol. 1993. PMID: 8157043 Clinical Trial.